Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338792 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01338792 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 47 participants.
The verdict
NCT01338792, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving oxaliplatin and pemetrexed disodium together works in treating patients with refractory hormone-resistant prostate cancer. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving oxaliplatin together with pemetrexed disodium may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- DRUG oxaliplatin
- DRUG pemetrexed disodium
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338792
The ClinicalTrials.gov registry entry for NCT01338792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01338792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338792 about?
NCT01338792 is a clinical study titled "Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer". This phase II trial studies how well giving oxaliplatin and pemetrexed disodium together works in treating patients with refractory hormone-resistant prostate cancer. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT01338792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2006-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01338792?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), oxaliplatin (DRUG), pemetrexed disodium (DRUG), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT01338792?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.